Editorial Picks
Hand-picked stories offering depth, insight, and perspective on global cannabis developments.
Editorial Picks · page 6
- Industry Trends
Cannabis Europa London 2026: The First Major Gathering Since Rescheduling Changed the Game
For many, last week’s rescheduling announcement threw a spanner in the works.
- Policy & Regulation
The US Officially Reschedules Cannabis, Partly….
After years of false starts, political delays and administrative paralysis, the United States federal government has taken its first concrete step toward rescheduling cannabis.
- Investment & Finance
Federal Agencies Reportedly Told to Prep for Imminent Cannabis Rescheduling Announcement
Cannabis stocks have once again been sent flying in the wake of the latest hint of progress on cannabis rescheduling from Trump’s White House.
- Industry Trends
Does the UK Media’s Cannabis Coverage Reflect Public Opinion? The Data Says No
This morning, the latest in a now-weekly series of stories in the British mainstream press was published in The Times, for the second week in a row taking aim at the advertising practices of some of the UK’s largest clinics.
- Hemp Industry
Eight Years After Decriminalisation, South Africa’s Cannabis Industry Edges Towards Regulated Market
South Africa, according to its own government, already has a cannabis industry worth up to R28bn (£1.28bn).
- Interviews
Bring It On: Meet the Cannabis CMO Welcoming Scrutiny With Open Arms
Scrutiny of the UK’s medical cannabis industry has rarely, if ever, been so acute since it was legalised in 2018.
- Medical Cannabis
The Right Reforms, the Wrong Narrative: Why the Medical Cannabis Debate Is Missing Half the Picture
Over the last few weeks, the UK’s medical cannabis industry has been written about in The Times, The Guardian, the BBC, The i Paper, Private Eye, and a swathe of other national and local publications.
- Medical Cannabis
Five Years, 74 Patients: Ireland Moves Forward With Review of Its Failing Medical Cannabis Programme
The Irish government has appointed a public health academic to chair a formal review of its now five-year-old Medical Cannabis Access Programme (MCAP) following months of parliamentary pressure.
- Opinion
Is the ‘Commercial Scale’ of Medical Cannabis in the UK Inappropriate?
As the UK’s medical cannabis industry continues to come under fierce scrutiny from the country’s mainstream media, James Duckenfield, CEO of UK-based cannabis cultivator Glass Pharms, argues that the focus should be on ensuring compliance with the existing regulatory framework rather than sensationalising a prescribing rate that remains a small fraction of demonstrable clinical need.
- UK & Europe
Züri Can Extended By Two Years As Results Point To Black Market Deterrence
Zurich’s municipal parliament has voted to extend its flagship adult-use cannabis pilot, Züri Can, by a further two years to October 2028, and to provide an additional CHF 800,000 in funding, in a 101-13 vote that laid bare the fault lines in Swiss cannabis politics.
- Industry Trends
Germany’s Cannabis Reform Shows No Signs of Harm its Critics Predicted, Government Mandated Data Shows
On the second anniversary of Germany’s landmark Cannabis Act (CanG) coming into force, the most comprehensive data and analysis of its impact to date has been published.
- Medical Cannabis
Oliver’s Law: The Campaign That Could Reshape UK Cannabis Prescribing
Written by Ben Stevens & Sarah Sinclair A new campaign is calling for urgent regulatory changes to how medical cannabis is prescribed to patients in the UK, following what is believed to be the first time a coroner has found that a prescription for cannabis contributed to a death in the country.
